Amgen to Acquire Micromet For $1.16B

Thousand Oaks-based Amgen announced today that it is acquiring Micromet, a biopharmaceuticals firm based in Germany and Rockville, Maryland, in a deal worth $1.16 billion. Amgen said it will pay $11 per share in cash for Micromet, which is developing treatments for acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), and other conditions.